TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03012360
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
Study: NCT01677689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
Study: NCT01169025
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
Study: NCT01259141
Drug: Cephalosporins and azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
Study: NCT03467347
Drug: VR: 200 mg DPV + 320 mg LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
Study: NCT01328769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04655690
Drug: NNC0471-0119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
Study: NCT00556075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily for 4 months
Study: NCT02428777
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral diclofenac 100 mg 1 hour before the procedure
Study: NCT02428777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo 1 hour before the procedure
Study: NCT05006235
Drug: Epinephrine Inhalation Solution
Normalized name: Epinephrine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05006235
Drug: Saline Inhalants
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02107833
Drug: OPRX-106
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02521168
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine is given peri-operatively through naso-gastric tube
Study: NCT02521168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consist of saccharin lactis that has the same appearance as Tetronine
Study: NCT01666990
Drug: TwHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Study: NCT01666990
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Study: NCT01800097
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
Study: NCT00176839
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
Study: NCT03833154
Drug: (Osimertinib cohort, single-arm, open-label separate cohort)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
Study: NCT00158028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo match in identical tablets
Study: NCT03534869
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
Study: NCT02689180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement of furosemide by placebo
Study: NCT00035490
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet, once daily for one year
Study: NCT00465192
Drug: estradiol, 10 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00465192
Drug: estradiol, 25 mcg
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00465192
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01662986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day (QD)
Study: NCT01215786
Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
Study: NCT01666704
Drug: Placebo matching with BMS-823778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0mg, Once daily, 1 year
Study: NCT04682483
Drug: Vasopressor
Normalized name: Vasopressor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
Study: NCT01215786
Drug: AGN-207281 vehicle ophthalmic solution (Placebo)
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
Study: NCT03339258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, or inactive pill.
Study: NCT00065260
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
Study: NCT02962258
Drug: Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, crossover
Study: NCT02962258
Drug: Tribenzor of Daichi Sankyo Inc. USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, crossover
Study: NCT03372785
Drug: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Study: NCT03314493
Drug: Spironolactone 25Mg Tablet
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with coronary calcium score \> 30 were treated with spironolactone for 12 months
Study: NCT03715517
Drug: Bupicavaine 0.125% epidural solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range 0.075-0.125 mL⋅kg-¹⋅h-¹
Study: NCT00432484
Drug: Lingzhi and Sen Miao San
Approvals — FDA: no, EMA: no, PMDA: no
Description: G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
Study: NCT02040623
Drug: R348 Ophthalmic Solution, 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
Study: NCT02040623
Drug: R348 Ophthalmic Solution, 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
Study: NCT04085991
Drug: 131I-PSMA-1095 Radioligand Therapy (RLT)
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
Study: NCT00111085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Study: NCT00796549
Drug: BiBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 in EGFR FISH positive NSCLC patients
Study: NCT01275105
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in each eye at designated visits
Study: NCT03281694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo skin patch and placebo oral solution
Study: NCT02617199
Drug: intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
Study: NCT03310645
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 different doses over the course of study
Study: NCT03310645
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for BAY1817080
Study: NCT00867867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.3 mg once per day, 6 days per week, for 9 months
Study: NCT03475524
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebos will be given to control beside trichloracetic acid peeling
Study: NCT03475524
Drug: Trichloroacetic Acid Peeling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichloroacetic acid peeling to the three groups
Study: NCT01208818
Drug: Cyclophosphamide + Bortezomib + Dexamethasone regimen
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect.
Study: NCT01198275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of olive oil,one capsule twice a day
Study: NCT00905450
Drug: BOL-303242-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
Study: NCT00905450
Drug: Vehicle for BOL-303242-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication instilled into the study eye, subjects randomized to various drug dose schedules.
Study: NCT00665665
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for s.c. injection
Study: NCT03007966
Drug: Epinephrine 1:200k
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as part of the local anesthetic mixture
Study: NCT03601780
Drug: usual care only
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual care only
Study: NCT03041948
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT03041948
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT03041948
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT01387594
Drug: lumbar puncture
Normalized name: Lumbar Puncture 18g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
Study: NCT01695460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04369586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02176538
Drug: Product 0405
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 0405 will be administered topically twice daily for 28 days
Study: NCT02176538
Drug: Placebo for Product 0405
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Study: NCT00553683
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01426269
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning
Study: NCT01426269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
Study: NCT02461264
Drug: Single red blood packed cells Transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02461264
Drug: Two packed red blood cells Transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00269789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03440892
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: folate antagonist
Study: NCT01638663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Unikalk 1 pr day for 1 day
Study: NCT04085419
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid 5 mg intravenously once a year
Study: NCT00604019
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine 5-20 mcg/kg/min to pre-determined max of 20
Study: NCT00604019
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
Study: NCT04189367
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks
Study: NCT00952302
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
Study: NCT02383108
Drug: DTG +DRV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
Study: NCT00952302
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
Study: NCT05042024
Drug: Oral L-arginine aspartate administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: The use of L-arginine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Study: NCT05042024
Drug: Oral L-ornithine aspartate administration
Normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The use of L-ornithine aspartate as adjuncts to local conservative treatment (scaling and root planing) of periodontitis to optimize treatment by modulating local macrophage subpopulations
Study: NCT02529995
Drug: AZD9291 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Study: NCT02529995
Drug: AZD9291 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
Study: NCT03239483
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal HEC placebo gel; administered rectally
Study: NCT00101010
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 IVPB on day 1
Study: NCT00101010
Drug: Pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m\^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
Study: NCT02706717
Drug: Visbiome Extra Strength
Normalized name: Visbiome Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Study: NCT02706717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
Study: NCT03737240
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
Study: NCT01893229
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine is used as a mood stabiliser
Study: NCT01179672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
Study: NCT04216251
Drug: AMR101
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
Study: NCT00835770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken to maintain the blind in the 240 mg BID treatment group.
Study: NCT00226538
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00226538
Drug: Diclophenac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03222323
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (saline) is administered perineurally in all but the perineural group.
Study: NCT01317758
Drug: AS03 Adjuvant
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
Study: NCT00998985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, orally, once a day for 7 days
Study: NCT02280525
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.
Study: NCT00444600
Drug: Sham injection + laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Study: NCT00333931
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00620997
Drug: Proparacaine drops 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical, 0.05% drops, PRN continuously for up to 7 days
Study: NCT00620997
Drug: saline drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline drops continuously PRN for up to 7 days
Study: NCT00139672
Drug: PD-217,014
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00477035
Drug: CIK cells
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x10e8 cells/kg
Study: NCT00477035
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/kg
Study: NCT03320434
Drug: PRT-2761 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six drops in each eye over a 17 day period.
Study: NCT03320434
Drug: PRT-2761 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six drops in each eye over a 17 day period.
Study: NCT03320434
Drug: PRT-2761 0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six drops in each eye over a 17 day period.
Study: NCT02561039
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
Study: NCT02637167
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.